Nordic Nanovector and LegoChem Biosciences collaborate to develop novel antibody-drug conjugates (ADCs) targeting leukaemias
Leukemias are orphan diseases with a significant unmet medical need, representing a growing market estimated to be worth more than $5 billion by 2024
Nordic Nanovector, is pleased to announce it has entered into a collaboration with LegoChem Biosciences, a South Korea-based biopharmaceutical company, to develop novel CD37-targeting antibody-drug conjugates (ADCs) for the treatment of leukaemias.
This collaboration supports Nordic Nanovector’s strategy to expand its pipeline of targeted therapies to include CD37-targeting antibody products conjugated to anticancer compounds that are not radionuclides. Such conjugates are commonly referred to as antibody-drug conjugates or ADCs.
Jostein Dahle, Nordic Nanovector’s Chief Scientific Officer, commented: 'We are delighted to expand our R&D activities into the ADC area, a strategic and natural progression for us given our expertise in antibodies and the prevalence of the CD37 antigen on many tumour cell types.'
We believe that anti-CD37 ADCs will have clinical characteristics that are beneficial for treating a range of haematological malignancies. Our strategy to build a pipeline of innovative antibody-radionuclide conjugates (ARCs) and ADCs based on our expertise and platform, and in collaboration with expert partners such as LegoChem, is aimed at creating multiple new product opportunities bringing new targeted treatments to patients,' he added.
'We are very excited to enter into this collaboration agreement to develop CD37-targeting ADCs with Nordic Nanovector, which has expertise with anti-CD37 antibodies and experience of advancing candidates into clinical research,' said Jeiwook Chae, Chief Business Development Officer of LegoChem.
'We strongly believe that our proprietary conjugation platform addresses significant unmet needs of current ADC technologies. With Nordic Nanovector’s deep expertise in antibodies and commitment to develop novel therapeutics, we are confident that we will further enrich the pipeline of next-generation ADCs and achieve our goals of advancing the landscape of cancer treatment and providing new clinical options for cancer patients,'